Results 151 to 160 of about 243,754 (245)

Rituximab use in adult primary glomerulopathy: where is the evidence?

Therapeutics and Clinical Risk Management, 2016
Samir G Mallat,1 Houssam S Itani,2 Rana M Abou-Mrad,3 Rima Abou Arkoub,4 Bassem Y Tanios1 1Division of Nephrology, Department of Internal Medicine, American University of Beirut Medical Center, 2Division of Nephrology, Department of Internal Medicine ...
Mallat SG, Itani HS, Abou-Mrad RM, Abou Arkoub R, Tanios BY   +4 more
doaj  

An Evaluation of the Level of Anti-phospholipase A2 Receptor (PLA2R) Antibody in Different Pathological Types of Glomerulonephritis

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2017
BACKGROUND AND OBJECTIVE: Nowadays, anti-phospholipase A2 receptor (PLA2R) antibody is recognized as a diagnostic biomarker for idiopathic membranous nephropathy (iMN) and is also used to assess disease progression.
F Sadadi, E Taherkhani, Sh Ossareh, T Shoshtarizadeh, HR Khoddami Vishteh   +4 more
doaj  

Treatment of High-Risk Idiopathic Membranous Nephropathy with Huaier Granules and RASi: A Case Series

International Medical Case Reports Journal
Tingyi Zhao, Hua Liang, Xiangdong Yang, Xiaoyan Xiao Department of Nephrology, Qilu Hospital of Shandong University, Jinan City, Shandong, People’s Republic of ChinaCorrespondence: Xiaoyan Xiao, Email xiaoyanxiao2007@163.comAbstract: Huaier Granules, an ...
Zhao T, Liang H, Yang X, Xiao X
doaj  

Diagnosis and treatment of primary glomerular diseases Membranous nephropathy, focal segmental glomerulosclerosis and IgA nephropathy.

, 2005
Item does not contain fulltextMembranous nephropathy, focal segmental glomerulosclerosis (FSGS) and IgA nephropathy are the most frequent and important primary glomerulopathies.
Deegens, J.K.J., Wetzels, J.F.M.
core  

Correlation of Glomerular MBL Deposition with the Clinicopathology and Prognosis of Idiopathic Membranous Nephropathy: A PLA2R Subgroup Analysis. [PDF]

Int J Gen Med
Pan Y, Zhao Y, Wu X, Chen B, Lu M, Shao D, Liu L, Chen W.   +7 more
europepmc   +1 more source

Clinical effect of obinutuzumab in the treatment of idiopathic membranous nephropathy. [PDF]

Am J Transl Res
Ning S, Zhang Q, Shang Z, Liu H.
europepmc   +1 more source

Is Rituximab Suitable for Patients with Idiopathic Membranous Nephropathy Who are Seronegative for Anti-PLA2R Antibody? [PDF]

Drug Des Devel Ther
Yang Y, Xie X, Yuan F, Zeng F, Wang Y, Zhang R, Yan W, Luo K, Ren D, Xu G.   +9 more
europepmc   +1 more source

Methylprednisolone plus Chlorambucil as Compared with Methylprednisolone alone for the Treatment of Idiopathic Membranous Nephropathy.

, 1992
CESANA, Bruno Mario, Ponticelli C, the Italian Idiopathic Membranous Nephropathy Treatment Study Group, Zucchelli P, Passerini P   +4 more
core   +1 more source

Histopathological predictors of renal outcomes in idiopathic membranous nephropathy with a focus on global sclerotic glomeruli ratio. [PDF]

Sci Rep
Tunca O, Turkmen A, Eren N, Yadigar S, Karagoz F, Dincer MT, Gok M, Cevher SK, Tatar E, Kutlay S, Karaca C, Basturk T, Dursun B, Duranay M, Ozler TE, Arikan H, Turkmen K, Yildiz A, Kazancıoğlu R, Kocyigit İ, Ulu S, Dheir H, Özdemir A, Karakan S, Azak A, Oguz EG, Yılmaz Z, Sahin G, Tanrisev M, Sengul E, Selcuk NY, Gul CB, Kaya B, Ogutmen MB, Oygar D, Turgutalp K, Sayarlioglu H, Gungor O, Islam M, Tahillioglu Y, Kazan S.   +40 more
europepmc   +1 more source

Idiopathic membranous nephropathy: management strategies.

, 2009
Treatment of idiopathic membranous nephropathy is based on a 'symptomatic' therapy that includes ACE inhibitors or angiotensin II receptor antagonists, and on an 'aetiological' therapy aimed at modulating underlying immunological mechanisms.
QUAGLIA, Marco, STRATTA, Piero
core